[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618502":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":154,"collaborators":20,"id":156,"slug":157,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":20,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":20,"enrollmentInfo":165,"targetDuration":20,"studyType":168,"phases":169,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving GSK5471713","EXPERIMENTAL","Participants will receive GSK5471713, according to their allocated dose level guided by the dose escalation study design.",[13],"Drug: GSK5471713",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","GSK5471713","GSK5471713 will be administered at different dose levels based on the dose escalation study design",[9],null,[22],{"name":23,"affiliation":5,"role":24},"GSK Clinical Trials","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":30},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[35,57,71,85,99,115,129,144],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"GSK Investigational Site","RECRUITING","La Jolla","California","92093","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.2742,32.84727,{"lat":47,"lon":46},[50,51,54],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":55,"role":56,"phone":20,"phoneExt":20,"email":20},"Rana McKay","PRINCIPAL_INVESTIGATOR",{"facility":36,"status":37,"city":58,"state":59,"zip":60,"country":41,"countryCode":42,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Grand Rapids","Michigan","49546",{"type":44,"coordinates":62},[63,64],-85.66809,42.96336,{"lat":64,"lon":63},[67,68,69],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":70,"role":56,"phone":20,"phoneExt":20,"email":20},"Emerson Lim",{"facility":36,"status":37,"city":72,"state":73,"zip":74,"country":41,"countryCode":42,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Philadelphia","Pennsylvania","19107",{"type":44,"coordinates":76},[77,78],-75.16362,39.95238,{"lat":78,"lon":77},[81,82,83],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":84,"role":56,"phone":20,"phoneExt":20,"email":20},"Kevin Zarrabi",{"facility":36,"status":37,"city":86,"state":87,"zip":88,"country":41,"countryCode":42,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"West Valley City","Utah","84119",{"type":44,"coordinates":90},[91,92],-112.00105,40.69161,{"lat":92,"lon":91},[95,96,97],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":98,"role":56,"phone":20,"phoneExt":20,"email":20},"Jose Pacheco",{"facility":36,"status":37,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Toronto","Ontario","M5G 2M9","Canada","CA",{"type":44,"coordinates":106},[107,108],-79.39864,43.70643,{"lat":108,"lon":107},[111,112,113],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":114,"role":56,"phone":20,"phoneExt":20,"email":20},"Srikala Sridhar",{"facility":36,"status":37,"city":116,"state":117,"zip":118,"country":103,"countryCode":104,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Montreal","Quebec","H4A 3J1",{"type":44,"coordinates":120},[121,122],-73.58781,45.50884,{"lat":122,"lon":121},[125,126,127],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":128,"role":56,"phone":20,"phoneExt":20,"email":20},"Ramy Saleh",{"facility":36,"status":37,"city":130,"state":20,"zip":131,"country":132,"countryCode":133,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Tokyo","104-0045","Japan","JP",{"type":44,"coordinates":135},[136,137],139.69171,35.6895,{"lat":137,"lon":136},[140,141,142],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":143,"role":56,"phone":20,"phoneExt":20,"email":20},"Kazuki Sudo",{"facility":36,"status":37,"city":130,"state":20,"zip":145,"country":132,"countryCode":133,"cosmosGeoPoint":146,"geoPoint":148,"contacts":149},"135-8550",{"type":44,"coordinates":147},[136,137],{"lat":137,"lon":136},[150,151,152],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":153,"role":56,"phone":20,"phoneExt":20,"email":20},"Yuji Miura",{"type":155,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100618502","phase-1-first-time-in-human-study-of-gsk5471713-in-adults-with-mcrpc-100618502",false,"NCT07332455","First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","A Phase 1\u002F2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)","Inclusion Criteria:\n\n* Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.\n* Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.\n* Progression on ADT and \\>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane based chemotherapy regimens.\n\nExclusion Criteria:\n\n* Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.\n* Impaired cardiac function or clinically significant cardiac disease.\n* Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.\n* Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion\u002Fexclusion criteria apply.","MALE","18 Years",{"count":166,"type":167},54,"ESTIMATED","INTERVENTIONAL",[170,171],"PHASE1","PHASE2","This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit\u002Frisk of GSK5471713 given as a monotherapy in mCRPC.",[174],"Neoplasms, Prostate",[176,177,17,178],"Metastatic castration-resistant prostate cancer","First-Time-in-Human","Prostate cancer","2026-06-17",{"date":181,"type":182},"2026-06-18","ACTUAL",{"date":184,"type":182},"2026-02-10",{"date":186,"type":167},"2030-03-26",{"name":5,"class":6},8]